New shot aims to stop the maddening itch of prurigo nodularis
NCT ID NCT06554509
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an injection called SHR-1819 to see if it can safely reduce the intense itching caused by prurigo nodularis, a chronic skin condition with hard, itchy bumps. About 423 adults will receive either the drug or a placebo, and researchers will track how much their worst itch improves over 16 to 24 weeks. The goal is to find a new treatment option for people who suffer from this distressing itch.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRURIGO NODULARIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University People's Hospital
RECRUITINGBeijing, Beijing Municipality, 100032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a CBD cream soothe Eczema's relentless itch?
- Can a biologic drug quiet the relentless itch of prurigo nodularis?
- Skin disease evolution under the microscope: a 17-Year look at what drives severity
- New drug aimed at calming the itch of prurigo nodularis enters human testing
- New injection shows promise for relieving intense itching
- New drug offers hope for severe itch from skin lumps